Home
Scholarly Works
Letter: comparative safety and efficacy of...
Journal article

Letter: comparative safety and efficacy of infliximab vs. adalimumab in Crohn's disease – should one consider disease location? Authors’ reply

Authors

Narula N; Reinisch W

Journal

Alimentary Pharmacology & Therapeutics, Vol. 44, No. 7, pp. 772–773

Publisher

Wiley

Publication Date

January 1, 2016

DOI

10.1111/apt.13768

ISSN

0269-2813

Contact the Experts team